Functional neurological disorder and placebo and nocebo effects: shared mechanisms.
Journal
Nature reviews. Neurology
ISSN: 1759-4766
Titre abrégé: Nat Rev Neurol
Pays: England
ID NLM: 101500072
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
accepted:
04
08
2022
pubmed:
9
9
2022
medline:
4
10
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
Functional neurological disorder (FND) is characterized by neurological symptoms that cannot be explained by a structural neurological cause. Among the different aetiological models that have been proposed for FND, of note is the Bayesian predictive coding model, which posits that perception relies on top-down cortical predictions (priors) to infer the source of incoming sensory information. This model can also apply to non-pathological experiences, such as placebo and nocebo effects, wherein sensory information is shaped by prior expectations and learning. To date, most studies of the relationship between placebo and nocebo effects and FND have focused on the use of placebos for diagnosis and treatment of FND. Here, we propose that this relationship might go beyond diagnosis and therapy. We develop a framework in which shared cognitive, personality and neuroanatomical factors justify the consideration of a deeper link between FND and placebo and nocebo effects. This new perspective might offer guidance for clarification of the pathogenesis of FND and for the identification of potential biomarkers and therapeutic targets.
Identifiants
pubmed: 36075980
doi: 10.1038/s41582-022-00711-z
pii: 10.1038/s41582-022-00711-z
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
624-635Informations de copyright
© 2022. Springer Nature Limited.
Références
Hallett, M. et al. Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol. 21, 537–550 (2022).
pubmed: 35430029
Reuber, M. & Brown, R. J. Understanding psychogenic nonepileptic seizures — phenomenology, semiology and the integrative cognitive model. Seizure 44, 199–205 (2017).
pubmed: 27988107
Edwards, M. J. & Bhatia, K. P. Functional (psychogenic) movement disorders: merging mind and brain. Lancet Neurol. 11, 250–260 (2012).
pubmed: 22341033
Keynejad, R. C. et al. Stress and functional neurological disorders: mechanistic insights. J. Neurol. Neurosurg. Psychiatry 90, 813–821 (2019).
pubmed: 30409887
Brown, R. J. Psychological mechanisms of medically unexplained symptoms: an integrative conceptual model. Psychol. Bull. 130, 793–812 (2004).
pubmed: 15367081
Stone, J. et al. The role of physical injury in motor and sensory conversion symptoms: a systematic and narrative review. J. Psychosom. Res. 66, 383–390 (2009).
pubmed: 19379954
Edwards, M. J., Adams, R. A., Brown, H., Pareés, I. & Friston, K. J. A Bayesian account of “hysteria”. Brain 135, 3495–3512 (2012).
pubmed: 22641838
pmcid: 3501967
Friston, K., Kilner, J. & Harrison, L. A free energy principle for the brain. J. Physiol. Paris. 100, 70–87 (2006).
pubmed: 17097864
Marotta, A. et al. Functional neurological disorders as seen by a cohort of general practitioners in northern Italy: evidence from an online survey. Front. Neurol. 12, 583672 (2021).
pubmed: 33569039
pmcid: 7868405
Barbey, A. et al. Management of functional neurological disorders (FND): experience from a Swiss FND clinic. Clin. Trans. Neurosci. 6, 2 (2022).
Pick, S. et al. Outcome measurement in functional neurological disorder: a systematic review and recommendations. J. Neurol. Neurosurg. Psychiatry 91, 638–649 (2020).
pubmed: 32111637
Benedetti, F. Placebo and the new physiology of the doctor–patient relationship. Physiol. Rev. 93, 1207–1246 (2013).
pubmed: 23899563
pmcid: 3962549
Colloca, L. & Miller, F. G. How placebo responses are formed: a learning perspective. Philos. Trans. R. Soc. B Biol. Sci. 366, 1859–1869 (2011).
Burke, M. J. et al. Leveraging the shared neurobiology of placebo effects and functional neurological disorder: a call for research. J. Neuropsychiatry Clin. Neurosci. 32, 101–104 (2020).
pubmed: 31662093
Edwards, M. J., Bathia, K. P. & Cordivari, C. Immediate response to botulinum toxin injections in patients with fixed dystonia. Mov. Disord. 26, 917–918 (2011).
pubmed: 21394784
Huys, A. C. M. L., Haggard, P., Bhatia, K. P. & Edwards, M. J. Misdirected attentional focus in functional tremor. Brain 144, 3436–3450 (2021).
pubmed: 34145898
pmcid: 8677517
McIntosh, R., McWhriter, L., Ludwig, L., Carson, A. & Stone, J. Attention and sensation in functional motor disorder. Neuropsychologia 106, 207–215 (2017).
pubmed: 28966140
Roelofs, K., van Galen, G. P., Eling, P., Keijsers, G. P. J. & Hoogduin, C. Endogenous and exogenous attention in patients with conversion paresis. Cogn. Neuropsychol. 20, 733–745 (2003).
pubmed: 20957591
Edwards, M. J., Fotopoulou, A. & Pareés, I. Neurobiology of functional (psychogenic) movement disorders. Curr. Opin. Neurol. 26, 442–447 (2013).
pubmed: 23823467
pmcid: 4196785
Pareés, I. et al. Failure of explicit movement control in patients with functional motor symptoms. Mov. Disord. 28, 517–523 (2013).
pubmed: 23408383
Gandolfi, M. et al. Motor dual task with eyes closed improves postural control in patients with functional motor disorders: a posturographic study. Gait Posture 88, 286–291 (2021).
pubmed: 34153806
Summerfield, C. & Egner, T. Expectation (and attention) in visual cognition. Trends Cogn. Sci. 13, 403–409 (2009).
pubmed: 19716752
Fiorio, M. et al. Enhancing non-noxious perception: behavioural and neurophysiological correlates of a placebo-like manipulation. Neuroscience 217, 96–104 (2012).
pubmed: 22569155
Posner, M. I., Snyder, C. R. & Davidson, B. J. Attention and the detection of signals. J. Exp. Psychol. 109, 160–174 (1980).
pubmed: 7381367
Palmer, T. E. The effects of contextual scenes on the identification of objects. Mem. Cogn. 3, 519–526 (1975).
von Helmholtz, H. V. Treatise on Psychological Optics (trans. Southall, J. P. C.) (Dover, 1962).
Corbetta, M. & Shulman, G. L. Control of goal-directed and stimulus-driven attention in the brain. Nat. Rev. Neurosci. 3, 201–215 (2002).
pubmed: 11994752
Mulckhuyse, M. & Dalmaijer, E. S. Distracted by danger: temporal and spatial dynamics of visual selection in the presence of threat. Cogn. Affect. Behav. Neurosci. 16, 315–324 (2016).
pubmed: 26546018
Bakvis, P., Spinhoven, P. & Roelofs, K. Basal cortisol is positively correlated to threat vigilance in patients with psychogenic nonepileptic seizures. Epilepsy Behav. 16, 558–560 (2009).
pubmed: 19818692
Reuber, M. The etiology of psychogenic non-epileptic seizures: toward a biopsychosocial model. Neurol. Clin. 27, 909–924 (2009).
pubmed: 19853215
Beissner, F. et al. Placebo-induced somatic sensations: a multi-modal study of three different placebo interventions. PLoS ONE 10, e0124808 (2015).
pubmed: 25901350
pmcid: 4406515
Colloca, L., Sigaudo, M. & Benedetti, F. The role of learning in nocebo and placebo effects. Pain 136, 211–218 (2008).
pubmed: 18372113
Vellemure, C. & Bushnell, C. M. Cognitive modulation of pain: how do attention and emotion influence pain processing? Pain 95, 195–199 (2002).
Geers, A. L., Helfer, S. G., Weiland, P. E. & Kosbab, K. Expectations and placebo response: a laboratory investigation into the role of somatic focus. J. Behav. Med. 29, 171–178 (2006).
pubmed: 16374671
Kirmayer, L. J. & Young, A. Culture and somatization: clinical, epidemiological, and ethnographic perspectives. Psychosom. Med. 60, 420–430 (1998).
pubmed: 9710287
van den Bergh, O., Witthöft, M., Petersen, S. & Brown, R. J. Symptoms and the body: taking the inferential leap. Neurosci. Biobehav. Rev. 74, 185–203 (2017).
pubmed: 28108416
Sharpe, D. & Faye, C. Non-epileptic seizures and child sexual abuse: a critical review of the literature. Clin. Psychol. Rev. 26, 1020–1040 (2006).
pubmed: 16472897
Jungilligens, J., Paredes-Echeverri, S., Popkirov, S., Barrett, L. F. & Perez, D. L. A new science of emotion: implications for functional neurological disorder. Brain https://doi.org/10.1093/brain/awac204 (2022).
doi: 10.1093/brain/awac204
pubmed: 35653495
Goldstein, L. H. & Mellers, J. D. Ictal symptoms of anxiety, avoidance behaviour, and dissociation in patients with dissociative seizures. J. Neurol. Neurosurg. Psychiatry 77, 616–621 (2006).
pubmed: 16614021
pmcid: 2117432
Wessely, S., Sharpe, M. & Hotopf, M. Chronic Fatigue and its Syndromes (Oxford Univ. Press, 1998).
Kirsch, I. Response expectancy as a determinant of experience and behavior. Am. Psychol. 40, 1189–1202 (1985).
Pareés, I. et al. “Jumping to conclusions” bias in functional movement disorders. J. Neurol. Neurosurg. Psychiatry 83, 460–463 (2012).
pubmed: 22338028
Kaptchuk, T. J., Hemond, C. C. & Miller, F. G. Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice. BMJ 370, m1668 (2020).
pubmed: 32690477
Büchel, C., Geuter, S., Sprenger, C. & Eippert, F. Placebo analgesia: a predictive coding perspective. Neuron 81, 1223–1239 (2014).
pubmed: 24656247
Colloca, L., Lopiano, L., Lanotte, M. & Benedetti, F. Overt versus covert treatment for pain, anxiety, and Parkinson’s disease. Lancet Neurol. 3, 679–684 (2004).
pubmed: 15488461
Pollo, A. et al. Response expectancies in placebo analgesia and their clinical relevance. Pain 93, 77–84 (2001).
pubmed: 11406341
van Laarhoven, A. I. et al. Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain 152, 1486–1494 (2011).
pubmed: 21353388
Benedetti, F. et al. Open versus hidden medical treatments: the patient’s knowledge about a therapy affects the therapy outcome. Prev. Treat. 6, 1a (2013).
Lidstone, S. C. et al. Effects of expectation on placebo induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 67, 857–865 (2010).
pubmed: 20679593
Kaptchuk, T. J. Open-label placebo: reflections on a research agenda. Perspect. Biol. Med. 61, 311–334 (2018).
pubmed: 30293971
Carvalho, C. et al. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain 157, 2766–2772 (2016).
pubmed: 27755279
pmcid: 5113234
Kaptchuk, T. J. et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE 5, e15591 (2010).
pubmed: 21203519
pmcid: 3008733
Ongaro, G. & Kaptchuk, T. J. Symptom perception, placebo effects, and the Bayesian brain. Pain 160, 1–4 (2019).
pubmed: 30086114
Jensen, K. B. et al. Nonconscious activation of placebo and nocebo pain responses. Proc. Natl Acad. Sci. USA 109, 15959–15964 (2012).
pubmed: 23019380
pmcid: 3465419
Fiorio, M., Emadi Andani, M., Marotta, A., Classen, J. & Tinazzi, M. Placebo-induced changes in excitatory and inhibitory corticospinal circuits during motor performance. J. Neurosci. 34, 3993–4005 (2014).
pubmed: 24623777
pmcid: 6705272
Benedetti, F., Pollo, A. & Colloca, L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions? J. Neurosci. 27, 11934–11939 (2007).
pubmed: 17978033
pmcid: 6673345
Pollo, A., Carlino, E. & Benedetti, F. The top‐down influence of ergogenic placebos on muscle work and fatigue. Eur. J. Neurosci. 28, 379–388 (2008).
pubmed: 18702709
Benedetti, F. et al. Teaching neurons to respond to placebos. J. Physiol. 594, 5647–5660 (2016).
pubmed: 26861164
pmcid: 5043026
Garcin, B. et al. Impact of transcranial magnetic stimulation on functional movement disorders: cortical modulation or a behavioral effect? Front. Neurol. 8, 338 (2017).
pubmed: 28769869
pmcid: 5515822
van den Bergh, O., Winters, W., Devriese, S. & van Diest, I. Learning subjective health complaints. Scand. J. Psychol. 43, 147–152 (2002).
pubmed: 12004952
Stegen, K., de Bruyne, K., Rasschaert, W., van de Woestijne, K. P. & van den Bergh, O. Fear-relevant images as conditioned stimuli for somatic complaints, respiratory behavior, and reduced end-tidal pCO
pubmed: 10067000
Wieder, L., Brown, R., Thompson, T. & Terhune, D. B. Suggestibility in functional neurological disorder: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 92, 150–157 (2021).
pubmed: 33219037
Eysenck, H. J. Suggestibility and hysteria. J. Neurol. Neurosurg. Psychiatry 6, 22–31 (1943).
Roelofs, K. et al. Hypnotic susceptibility in patients with conversion disorder. J. Abnorm. Psychol. 111, 390–395 (2002).
pubmed: 12003460
Deeley, Q. Hypnosis as a model of functional neurologic disorders. Handb. Clin. Neurol. 139, 95–103 (2016).
pubmed: 27719881
Phillips, W., Price, J., Molyneux, P. D. & Deeley, Q. Hypnosis. Pract. Neurol. 22, 42–47 (2022).
pubmed: 34389642
Roelofs, K., Hoogduin, K. A. L. & Keijsers, G. P. J. Motor imagery during hypnotic arm paralysis in high and low hypnotizable subjects. Int. J. Clin. Exp. Hypn. 50, 51–66 (2002).
pubmed: 11783441
Moene, F. C., Spinhoven, P., Hoogduin, K., Sandyck, P. & Roelofs, K. Hypnotizability, dissociation and trauma in patients with a conversion disorder: an exploratory study. Clin. Psychol. Psychother. 8, 400–410 (2001).
de Pascalis, V., Chiaradia, C. & Carotenuto, E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. Pain 96, 393–402 (2002).
pubmed: 11973014
de Pascalis, V. & Scacchia, P. Hypnotizability and placebo analgesia in waking and hypnosis as modulators of auditory startle responses in healthy women: an ERP study. PLoS ONE 11, e0159135 (2016).
pubmed: 27486748
pmcid: 4972439
Huys, A. C. M. L., Beck, B., Haggard, P., Bhatia, K. P. & Edwards, M. J. No increased suggestibility to placebo in functional neurological disorder. Eur. J. Neurol. 28, 2367–2371 (2021).
pubmed: 33690909
Jalilianhasanpour, R. et al. Resilience linked to personality dimensions, alexithymia and affective symptoms in motor functional neurological disorders. J. Psychosom. Res. 107, 55–61 (2018).
pubmed: 29502765
pmcid: 5856107
Bokharey, I. Z. Resilience and coping strategies in the patients with conversion disorder and general medical conditions: a comparative study. Malays. J. Psychiatry 22, 39–50 (2013).
Demartini, B. et al. The role of alexithymia in the development of functional motor symptoms (conversion disorder). J. Neurol. Neurosurg. Psychiatry 85, 1132–1137 (2014).
pubmed: 24610939
Perez, D. L. et al. Corticolimbic structural alterations linked to health status and trait anxiety in functional neurological disorder. J. Neurol. Neurosurg. Psychiatry 88, 1052–1059 (2017).
pubmed: 28844071
Macchi, Z. A., Kletenik, I., Olvera, C. & Holden, S. K. Psychiatric comorbidities in functional movement disorders: a retrospective cohort study. Mov. Disord. Clin. Pract. 8, 725–732 (2021).
pubmed: 34307745
pmcid: 8287186
Rady, A., Elfatatry, A., Molokhia, T. & Radwan, A. Psychiatric comorbidities in patients with psychogenic nonepileptic seizures. Epilepsy Behav. 118, 107918 (2021).
pubmed: 33735815
Anderson, K. E. et al. Impact of psychogenic movement disorders versus Parkinson’s on disability, quality of life, and psychopathology. Mov. Disord. 22, 2204–2209 (2007).
pubmed: 17876850
Bakvis, P. et al. Trauma, stress, and preconscious threat processing in patients with psychogenic nonepileptic seizures. Epilepsia 50, 1001–1011 (2009).
pubmed: 19170739
Bakvis, P., Spinhoven, P., Putman, P., Zitman, F. G. & Roelofs, K. The effect of stress induction on working memory in patients with psychogenic nonepileptic seizures. Epilepsy Behav. 19, 448–454 (2010).
pubmed: 20943444
Kranick, S. et al. Psychopathology and psychogenic movement disorders. Mov. Disord. 26, 1844–1850 (2011).
pubmed: 21714007
pmcid: 4049464
Baur, V., Hänggi, J. & Jäncke, L. Volumetric associations between uncinate fasciculus, amygdala, and trait anxiety. BMC Neurosci. 13, 4 (2012).
pubmed: 22217209
pmcid: 3398321
Kuhn, S., Schubert, F. & Gallinat, J. Structural correlates of trait anxiety: reduced thickness in medial orbitofrontal cortex accompanied by volume increase in nucleus accumbens. J. Affect. Disord. 134, 315–319 (2011).
pubmed: 21705088
Spampinato, M. V., Wood, J. N., de Simone, V. & Grafman, J. Neural correlates of anxiety in healthy volunteers: a voxel-based morphometry study. J. Neuropsychiatry Clin. Neurosci. 21, 199–205 (2009).
pubmed: 19622691
Blackmon, K. et al. Structural evidence for involvement of a left amygdala–orbitofrontal network in subclinical anxiety. Psychiatry Res. Neuroimaging 194, 296–303 (2011).
Kern, A., Kramm, C., Witt, C. M. & Barth, J. The influence of personality traits on the placebo/nocebo response: a systematic review. J. Psychosom. Res. 128, 109866 (2020).
pubmed: 31760341
Benedetti, F., Lanotte, M., Lopiano, L. & Colloca, L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 147, 260–271 (2007).
pubmed: 17379417
Benedetti, F., Amanzio, M., Vighetti, S. & Asteggiano, G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J. Neurosci. 26, 12014–12022 (2006).
pubmed: 17108175
pmcid: 6674855
Hebb, A. L., Poulin, J. F., Roach, S. P., Zacharko, R. M. & Drolet, G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1225–1238 (2005).
pubmed: 16242828
Bradwejn, J. & Koszycki, D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand. J. Clin. Lab. Invest. 61, 19–27 (2001).
Benedetti, F., Amanzio, M., Giovannelli, F., Craigs-Brackhahn, K. & Shaibani, A. Hypothalamic–pituitary–adrenal activity in adverse events reporting after placebo administration. Clin. Pharmacol. Ther. 110, 1349–1357 (2021).
pubmed: 34365636
Uhlenhuth, E. H. et al. Medication side effects in anxious patients: negative placebo responses? J. Affect. Disord. 47, 183–190 (1998).
pubmed: 9476759
Planès, S., Villier, C. & Mallaret, M. The nocebo effect of drugs. Pharmacol. Res. Perspect. 4, e00208 (2016).
pubmed: 27069627
pmcid: 4804316
Barsky, A. J., Saintfort, R., Rogers, M. P. & Borus, J. F. Nonspecific medication side effects and the nocebo phenomenon. Jama 287, 622–627 (2002).
pubmed: 11829702
Bekhuis, E., Boschloo, L., Rosmalen, J. G. & Schoevers, R. A. Differential associations of specific depressive and anxiety disorders with somatic symptoms. J. Psychosom. Res. 78, 116–122 (2015).
pubmed: 25524436
Agosti, V., Quitkin, F. M., Stewart, J. W. & McGrath, P. J. Somatization as a predictor of medication discontinuation due to adverse events. Int. Clin. Psychopharmacol. 17, 311–314 (2002).
pubmed: 12409685
Colagiuri, B. & Quinn, V. F. Autonomic arousal as a mechanism of the persistence of nocebo hyperalgesia. J. Pain. 19, 476–486 (2018).
pubmed: 29269281
Robbins, N. M., Larimer, P., Bourgeois, J. A. & Lowenstein, D. H. Number of patient-reported allergies helps distinguish epilepsy from psychogenic nonepileptic seizures. Epilepsy Behav. 55, 174–177 (2016).
pubmed: 26803428
pmcid: 4747833
Aybek, S. et al. Emotion–motion interactions in conversion disorder: an fMRI study. PLoS ONE 10, e0123273 (2015).
pubmed: 25859660
pmcid: 4393246
Voon, V. et al. Emotional stimuli and motor conversion disorder. Brain 133, 1526–1536 (2010).
pubmed: 20371508
pmcid: 2859149
Voon, V., Brezing, C., Gallea, C. & Hallett, M. Aberrant supplementary motor complex and limbic activity during motor preparation in motor conversion disorder. Mov. Disord. 26, 2396–2403 (2011).
pubmed: 21935985
pmcid: 4162742
Apazoglou, K., Mazzola, V., Wegrzyk, J., Polara, G. F. & Aybek, S. Biological and perceived stress in motor functional neurological disorders. Psychoneuroendocrinology 85, 142–150 (2017).
pubmed: 28863348
Voon, V. et al. Functional neuroanatomy and neurophysiology of functional neurological disorders (conversion disorder). J. Neuropsychiatry Clin. Neurosci. 28, 168–190 (2016).
pubmed: 26900733
Ashar, Y. K., Chang, L. J. & Wager, T. D. Brain mechanisms of the placebo effect: an affective appraisal account. Annu. Rev. Clin. Psychol. 13, 73–89 (2017).
pubmed: 28375723
Furmark, T. et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J. Neurosci. 28, 13066–13074 (2008).
pubmed: 19052197
pmcid: 6671592
Atlas, L. Y. et al. Dissociable influences of opiates and expectations on pain. J. Neurosci. 32, 8053–8064 (2012).
pubmed: 22674280
pmcid: 3387557
Eippert, F. et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63, 533–543 (2009).
pubmed: 19709634
Zhang, W., Qin, S., Guo, J. & Luo, J. A follow-up fMRI study of a transferable placebo anxiolytic effect. Psychophysiol 48, 1119–1128 (2011).
Egorova, N., Benedetti, F., Gollub, R. L. & Kong, J. Between placebo and nocebo: response to control treatment is mediated by amygdala activity and connectivity. Eur. J. Pain. 24, 580–592 (2020).
pubmed: 31770471
Levy, I. & Schiller, D. Neural computations of threat. Trends Cogn. Sci. 25, 151–171 (2021).
pubmed: 33384214
Zhang, S., Mano, H., Hanesh, G., Robbins, T. & Seymour, B. Dissociable learning processes underlie human pain conditioning. Curr. Biol. 26, 52–58 (2016).
pubmed: 26711494
pmcid: 4712170
Rommelfanger, K. S. The role of placebo in the diagnosis and treatment of functional neurologic disorders. Handb. Clin. Neurol. 139, 607–617 (2016).
pubmed: 27719875
Devinsky, O. & Fisher, R. Ethical use of placebos and provocative testing in diagnosing nonepileptic seizures. Neurology 47, 866–870 (1996).
pubmed: 8857710
Kaas, B. M., Humbyrd, C. J. & Pantelyat, A. Functional movement disorders and placebo: a brief review of the placebo effect in movement disorders and ethical considerations for placebo therapy. Mov. Disord. Clin. Pract. 5, 471–478 (2018).
pubmed: 30515436
pmcid: 6207108
Bartels, D. J. P. et al. Minimizing nocebo effects by conditioning with verbal suggestion: a randomized clinical trial in healthy humans. PLoS ONE 12, e0182959 (2017).
pubmed: 28910291
pmcid: 5598922
Darragh, M., Booth, R. J. & Consedine, N. S. Who responds to placebos? Considering the “placebo personality” via a transactional model. Psychol. Health Med. 20, 287–295 (2015).
pubmed: 25026092
Lorber, W., Mazzoni, G. & Kirsch, I. Illness by suggestion: expectancy, modeling, and gender in the production of psychosomatic symptoms. Ann. Behav. Med. 33, 112–116 (2007).
pubmed: 17291177
Benedetti, F., Durando, J. & Vighetti, S. Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase–prostaglandins pathway. Pain 155, 921–928 (2014).
pubmed: 24462931
di Blasi, Z., Harkness, E., Ernst, E., Georgiou, A. & Kleijnen, J. Influence of context effect on health outcomes: a systematic review. Lancet 357, 757–762 (2001).
pubmed: 11253970
Howe, L. C., Goyer, J. P. & Crum, A. J. Harnessing the placebo effect: exploring the influence of physician characteristics on placebo response. Health Psychol. 36, 1074–1082 (2017).
pubmed: 28277699
pmcid: 7608626
Nielsen, G., Buszewicz, M., Edwards, M. J. & Stevenson, F. A qualitative study of the experiences and perceptions of patients with functional motor disorder. Disab. Rehab. 42, 2043–2048 (2020).
Espay, A. J. et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 75, 1132–1141 (2018).
pubmed: 29868890
pmcid: 7293766
Stone, J. & Vermeulen, M. Functional sensory symptoms. Handb. Clin. Neurol. 139, 271–281 (2016).
pubmed: 27719847
Bell, H. A. et al. Functional cognitive disorder: dementia’s blind spot. Brain 143, 2895–2903 (2020).
Yon, D. & Frith, C. D. Precision and the Bayesian brain. Curr. Biol. 31, R1026–R1032 (2021).
pubmed: 34520708
Friston, K. J., Parr, T. & de Vries, B. The graphical brain: belief propagation and active inference. Netw. Neurosci. 1, 381–414 (2017).
pubmed: 29417960
pmcid: 5798592
Rommelfanger, K. S. Opinion: a role for placebo therapy in psychogenic movement disorders. Nat. Rev. Neurol. 9, 351–356 (2013).
pubmed: 23628738
Fahn, S. & Williams, D. T. Psychogenic dystonia. Adv. Neurol. 50, 431–455 (1988).
pubmed: 3400501
Factor, S. A., Podskalny, G. D. & Molho, E. S. Psychogenic movement disorders: frequency, clinical profile, and characteristics. J. Neurol. Neurosurg. Psychiatry 59, 406–412 (1995).
pubmed: 7561921
pmcid: 486078
Baik, J. S. Attention in Parkinson’s disease mimicking suggestion in psychogenic movement disorder. J. Mov. Disord. 5, 53 (2012).
pubmed: 24868415
pmcid: 4027663
Hall-Patch, L. et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia 51, 70–78 (2010).
pubmed: 19453708
Carson, A., Ludwig, L. & Welch, K. Psychologic theories in functional neurologic disorders. Handb. Clin. Neurol. 139, 105–120 (2016).
pubmed: 27719831
Baslet, G., Ehlert, A., Oser, M. & Dworetzky, B. A. Mindfulness-based therapy for psychogenic nonepileptic seizures. Epilepsy Behav. 103, 106534 (2020).
pubmed: 31680023
Larsson, M. J., Steffen, P. R. & Primosch, M. The impact of a brief mindfulness meditation intervention on cognitive control and error-related performance monitoring. Front. Hum. Neurosci. 7, 308 (2013).
Howlett, S. & Reuber, M. An augmented model of brief psychodynamic interpersonal therapy for patients with nonepileptic seizures. Psychotherapy 46, 125–138 (2009).
pubmed: 22122575
Mogg, K. & Bradley, B. P. Anxiety and attention to threat: cognitive mechanisms and treatment with attention bias modification. Behav. Res. Ther. 87, 76–108 (2016).
pubmed: 27616718
Richardson, M., Isbister, G. & Nicholson, B. A novel treatment protocol (Nocebo Hypothesis Cognitive Behavioural Therapy; NH-CBT) for functional neurological symptom disorder/conversion disorder: a retrospective consecutive case series. Behav. Cogn. Psychother. 46, 497–503 (2018).
pubmed: 29463338
Richardson, M., Kleinstäuber, M. & Wong, D. Nocebo-Hypothesis Cognitive Behavioral Therapy (NH-CBT) for persons with functional neurological symptoms (motor type): design and implementation of a randomized active-controlled trial. Front. Neurol. 11, 586359 (2020).
pubmed: 33424742
pmcid: 7793953
Moene, F. C., Spinhoven, P., Hoogduin, K. A. L. & van Dyck, R. A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type. Int. J. Clin. Exp. Hypn. 51, 29–50 (2003).
pubmed: 12825917